Latest Insider Transactions at Roivant Sciences Ltd. (ROIV)
This section provides a real-time view of insider transactions for Roivant Sciences Ltd. (ROIV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Roivant Sciences Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Roivant Sciences Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2025
|
Eric Venker President & Immunovant CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,051
-0.47%
|
$141,020
$20.27 P/Share
|
|
Nov 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,235
-0.32%
|
$24,700
$20.27 P/Share
|
|
Nov 19
2025
|
Keith S Manchester |
SELL
Open market or private sale
|
Indirect |
1,300,000
-1.71%
|
$26,000,000
$20.21 P/Share
|
|
Nov 19
2025
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
1,300,000
-1.71%
|
$26,000,000
$20.21 P/Share
|
|
Nov 19
2025
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
1,300,000
-1.71%
|
$26,000,000
$20.21 P/Share
|
|
Nov 17
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
539,650
-1.58%
|
$10,793,000
$20.51 P/Share
|
|
Nov 14
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,027,670
-2.92%
|
$20,553,400
$20.33 P/Share
|
|
Nov 13
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
287,283
-0.81%
|
$5,745,660
$20.81 P/Share
|
|
Nov 07
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
200,000
-11.73%
|
$4,000,000
$20.22 P/Share
|
|
Nov 07
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+10.5%
|
$600,000
$3.85 P/Share
|
|
Oct 20
2025
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
281
-0.24%
|
$4,777
$17.74 P/Share
|
|
Oct 20
2025
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
1,507
+1.25%
|
-
|
|
Oct 20
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-0.15%
|
$2,686
$17.74 P/Share
|
|
Oct 20
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
789
+0.72%
|
-
|
|
Oct 20
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,056
+1.82%
|
-
|
|
Oct 17
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
118,418
-7.29%
|
$2,013,106
$17.06 P/Share
|
|
Oct 17
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
118,418
+6.8%
|
$1,776,270
$15.85 P/Share
|
|
Oct 16
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
318,282
-17.46%
|
$5,410,794
$17.05 P/Share
|
|
Oct 16
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
318,282
+14.86%
|
$4,774,230
$15.85 P/Share
|
|
Oct 15
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
414,683
-21.6%
|
$6,634,928
$16.93 P/Share
|
|
Oct 15
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
414,683
+17.76%
|
$6,220,245
$15.85 P/Share
|
|
Oct 13
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
20,727
-1.36%
|
$331,632
$16.25 P/Share
|
|
Oct 13
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,727
+1.34%
|
$310,905
$15.85 P/Share
|
|
Oct 09
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
104,940
-6.52%
|
$1,679,040
$16.3 P/Share
|
|
Oct 09
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
104,940
+6.12%
|
$1,574,100
$15.85 P/Share
|
|
Oct 08
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
138,602
-8.43%
|
$2,217,632
$16.2 P/Share
|
|
Oct 08
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
138,602
+3.96%
|
$1,524,622
$11.65 P/Share
|
|
Oct 07
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
355,161
-19.09%
|
$5,682,576
$16.15 P/Share
|
|
Oct 07
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
355,161
+6.32%
|
$3,196,449
$9.05 P/Share
|
|
Oct 06
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
171,396
-10.22%
|
$2,742,336
$16.34 P/Share
|
|
Oct 06
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
171,396
+3.28%
|
$1,542,564
$9.05 P/Share
|
|
Sep 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,341
-0.6%
|
$35,115
$15.17 P/Share
|
|
Sep 23
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
611,000
-28.88%
|
$8,554,000
$14.83 P/Share
|
|
Sep 22
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
416,182
-8.5%
|
$6,242,730
$15.0 P/Share
|
|
Sep 22
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
562,374
+9.89%
|
$1,687,122
$3.85 P/Share
|
|
Sep 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-0.54%
|
$31,935
$15.04 P/Share
|
|
Sep 19
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
683,818
-25.77%
|
$9,573,452
$14.95 P/Share
|
|
Sep 19
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000,000
+27.37%
|
$3,000,000
$3.85 P/Share
|
|
Sep 18
2025
|
Matthew Gline CEO |
BUY
Open market or private purchase
|
Direct |
3,315
+0.02%
|
$49,725
$15.07 P/Share
|
|
Sep 10
2025
|
Epperly Melissa B, |
SELL
Other acquisition or disposition
|
Direct |
1,661
-2.89%
|
$21,593
$13.77 P/Share
|
|
Sep 10
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+20.16%
|
-
|
|
Sep 10
2025
|
James C Momtazee |
SELL
Other acquisition or disposition
|
Direct |
3,282
-2.95%
|
$42,666
$13.77 P/Share
|
|
Sep 10
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+11.55%
|
-
|
|
Sep 10
2025
|
Ilan Oren |
SELL
Other acquisition or disposition
|
Direct |
2,043
-1.71%
|
$26,559
$13.77 P/Share
|
|
Sep 10
2025
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+10.86%
|
-
|
|
Sep 10
2025
|
Meghan Fitzgerald |
SELL
Other acquisition or disposition
|
Direct |
937
-2.13%
|
$12,181
$13.77 P/Share
|
|
Sep 10
2025
|
Meghan Fitzgerald |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+24.86%
|
-
|
|
Sep 10
2025
|
Daniel Allen Gold |
SELL
Other acquisition or disposition
|
Direct |
5,270
-0.06%
|
$68,510
$13.77 P/Share
|
|
Sep 10
2025
|
Daniel Allen Gold |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+0.16%
|
-
|
|
Sep 10
2025
|
Keith S Manchester |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+0.74%
|
-
|